U rinary incontinence is the involuntary loss of urine. It is a common ailment that affects up to 50% of women within their lifetime, and has a detrimental effect on quality of life. There are many effective treatments, including conservative and medical management, available in the community before referral to secondary care. It is essential that GPs have a good understanding of the assessment, primary management and indications for onward referral of this common complaint that has a significant impact on quality of life.
Definitions and the scope of the problem
The International Continence Society defines urinary incontinence as the complaint where there is any involuntary leakage of urine. Risk factors for this include age, parity, obesity and genital syndrome of the menopause (vaginal atrophy). Urinary incontinence in women has a reported prevalence of up to 42% in the UK population, increasing to 60% in older adults in institutional care (Hunskaar et al., 2004) . There are significant social factors in the reporting of this problem to healthcare professionals, with urinary incontinence being viewed by many patients as an inevitable part of ageing, especially after childbirth. Many women are hesitant to report urinary incontinence, due to embarrassment. However, its impact on quality of life can be considerable, including effects on sexual function and relationships, ability to exercise, as well as employment and social life (Sinclair and Ramsey, 2011) .
Female urinary incontinence can be divided into a number of aetiologies, the most common being stress urinary incontinence and urgency urinary incontinence (see Table 1 ). Other possible causes include vesicovaginal fistulae, neurological bladder problems (such as those caused by multiple sclerosis, spina bifida and spinal cord injury), dementia and functional urinary incontinence (i.e. medically unexplained). It is important to be able to classify the aetiology of the urinary incontinence symptoms suffered by the patient, as this will inform management options for the GP.
Stress urinary incontinence (SUI) occurs when the pressure exerted upon the bladder exceeds the pressure of the urethral sphincter to stay closed. This can be caused by anything that results in an increase in intra-abdominal (and therefore also intra-vesical) pressure. SUI can occur with coughing, sneezing, laughing, heavy lifting, physical exercise and walking: downhill walking is particularly associated with SUI. Urinary leakage may also occur with sexual intercourse (coital incontinence), typically this occurs during penetration. Some women will avoid sexual activity due to this issue.
Overactive bladder (OAB) symptoms consist of frequency (voiding occurs more frequently than previously deemed normal by the affected patient), nocturia (waking from sleep to pass urine), urgency (the complaint of a sudden, compelling desire to pass urine that is difficult to defer) and urgency incontinence (involuntary leakage of urine associated with urgency). Patients may also complain of nocturnal enuresis (bedwetting) or coital incontinence (particularly during orgasm). Overactive bladder symptoms can occur when detrusor contractions happen during bladder filling. The detrusor muscle in the bladder should remain relaxed, other than during voiding. Involuntary detrusor contractions result in frequency, nocturia, urgency and sometimes urge incontinence (OAB wet). OAB syndrome can be exacerbated by caffeine and alcohol, as well as some foods (e.g. tomato-based foods). Many patients reduce their fluid intake to try and prevent leakage, however, this results in more concentrated urine that can irritate the bladder, further exacerbating OAB symptoms.
History and initial assessment
When a patient first reports leakage of urine, their initial descriptions may give clues as to the type of incontinence experienced, for example, women with urgency and urge incontinence may report avoiding going to unfamiliar places, or making sure they know the location of all the nearest toilets ('toilet mapping'). Women with stress incontinence may report worsening with a recent cough, or avoiding exercise classes for fear of leakage. Table 1 demonstrates some questions that can be helpful in determining the type of incontinence experienced. Asking women about their voiding frequency and fluid intake will give an insight into symptoms of frequency, nocturia, and bladder capacity. A frequency-volume chart (bladder diary) usually undertaken over 3 days and completed by the patient will provide this information, as well as recording frequency of incontinence episodes. It is important to enquire about symptoms that may be indicative of another diagnosis such as dysuria suggestive of urinary tract infection (UTI), or excessive thirst with polydipsia in diabetes.
A urine dipstick test should also be performed. If this reveals the presence of leucocytes or nitrites and the patient is experiencing symptoms of UTI, an appropriate course of antibiotics should be prescribed, pending culture results. In asymptomatic women with a urine dipstick test positive for leucocytes or nitrites, urine should be sent for microscopy, culture and sensitivity, and antibiotics prescribed based on culture result. In women with symptoms of UTI, but a negative urine dipstick test, send urine for culture and consider prescribing antibiotics.
It is crucial to ask and document for any patients presenting with lower urinary tract symptoms if they have any 'red flag' symptoms, including haematuria, weight loss, abdominal bloating or distension, which may be suggestive of underlying malignancy. The National Institute for Health and Care Excellence (NICE) national guidelines 123 (NICE, 2019a) advise that clinicians' initial assessment also includes enquiries to 'identify relevant predisposing and precipitating factors and other diagnoses that may require referral for additional investigation and treatment'. This refers to other conditions that may be present in patients with SUI and will usually be identified from the history or found on examination. Some specified indications that may need referral to a specialist service are listed in Box 1.
Examination
Abdominal palpation may reveal a distended bladder or a pelvic mass. Suprapubic tenderness may suggest an UTI. Due to the need for a chaperone and time constraints, patients may need to be brought back for a second appointment for pelvic examination with both a Cusco bivalve speculum and bimanual examination, which should be undertaken in all women with urinary incontinence. This should not be overlooked, as it can identify potential causes such as a pelvic mass resulting in overflow incontinence, or pelvic organ prolapse, which can be associated with OAB symptoms or voiding A cough test should be undertaken; the patient is asked to cough to assess for stress leakage while in the supine position with legs abducted. If leakage is seen with coughing, this is highly suggestive of SUI. Pelvic floor tone should be assessed and graded using the modified Oxford scale (see Table 2 ). This helps to identify whether patients are likely to do well with physiotherapy, as those with incontinence despite a modified Oxford score of 4þ may not benefit significantly from pelvic floor muscle training under the care of a women's health physiotherapist.
Management of SUI in primary care
All patients with SUI should be offered conservative management before referral to secondary care for investigation and management. As stress incontinence occurs when intraabdominal pressure causes intra-vesical pressure to overcome urethral pressure, weight loss for those with a body mass index over 30 kg/m 2 is beneficial. Guided pelvic floor muscle training (PFMT) with a specialist women's' health physiotherapist has been extensively proven to be an effective treatment for SUI, as well as improving the situation for those with both mixed and urgency incontinence (Dumoulin et al., 2018) . A course of guided PFMT will be sufficient treatment for up to half of patients with SUI, and all patients with SUI should be offered this option. This should be undertaken for a minimum duration of 3 months, and continued if beneficial. There is no evidence to support the use of self-directed pelvic floor muscle exercises guided by information leaflets, despite this being standard practice for many GPs. This practice should be discontinued, and supervised pelvic floor muscle exercises under the care of a women's health physiotherapist should be the standard of care. NICE does not recommend the use of duloxetine, which is a selective serotonin and norepinephrine reuptake inhibitor, as first line treatment for women with SUI or SUI-predominant mixed incontinence. NICE states that it can be considered for second line treatment in women who prefer pharmacological treatment over surgery or physiotherapy, or those in whom surgical treatment is not advised (NICE, 2019a) .
Vaginal devices such as Contiform Õ and Incostress Õ are designed to be inserted into the vagina by the patient for use during activities that may provoke SUI. They act by providing pressure on the urethra via the vagina and reduce stress leakage. Some devices are available on prescription, and women's health physiotherapists are able to provide patients with advice on their use. Many pharmacies and department stores now stock these types of devices. These can be especially valuable if the patient leaks in specific situations, such as when they are jogging. Some women are able to achieve the same effect by inserting a large size tampon.
Management of SUI in secondary care
If conservative management of SUI fails to improve symptoms, a referral to a urogynaecologist should be made. Urogynaecologists should be able to offer patients further investigations and a choice of interventions.
Most urogynaecologists will undertake urodynamic studies on patients with SUI. Urodynamics involves the siting of urethral and rectal catheters that have attached transducers to measure pressure. The bladder is then filled artificially via the catheter at a rate of usually around 50 mL/ minute to around 400-500 mL. The patient is asked to cough and strain at various points during the study to identify stress incontinence, and urgency urinary incontinence is tested for by asking the patient to wash their hands, listen to running water and wait before passing urine at the end of the test. The patient's voiding function is also assessed with the urinary flow rate and bladder pressures during voiding being measured. Urodynamics is important, as it allows for the diagnosis of stress incontinence to be confirmed and detrusor overactivity to be identified if present. The NICE guidelines (NICE, 2019a) state that urodynamic studies need not be undertaken in patients with pure stress incontinence and a positive cough test. However, many urogynaecologists will undertake urodynamics in these patients; not only to assess voiding function, but also to rule out detrusor Box 1. Indications for consideration of referral to a specialist service (urogynaecology/urology).
. Adapted from Laycock and Jerwood (2001) .
InnovAiT overactivity, which, if present, may worsen significantly following surgical treatment for SUI. The four main surgical procedures available for SUI are described in detail in Table 3 . Colposuspension supports the neck of the bladder by placing stitches into the vaginal tissue either side of the bladder neck and attaching them to the ileopectineal ligament behind the pubic bone. This can be performed either as an open procedure with a small low transverse incision, or laparoscopically. Rectus autologous fascial sling procedures also use a small low transverse incision. A small strip of rectus sheath is excised to create a sling, which is placed via an incision in the vagina around the urethra and secured above the rectus fascia through the abdominal incision. The 2019 NICE guidance regarding mid-urethral mesh tapes for stress incontinence specifies that only retro-pubic tapes should be offered, with strict conditions around both recording these procedures and clinical governance processes. At the time of writing, the national pause on the use of mesh for stress urinary incontinence remains ongoing (Gray et al., 2019) . All invasive procedures for treatment of SUI must be referred for discussion in the urogynaecology multidisciplinary team (MDT) meeting prior to surgical intervention as per the NICE guidelines (NICE, 2013 (NICE, , 2019a .
A less invasive surgical treatment for SUI is the use of bladder neck bulking agents (Fig. 1) . The non-absorbable bulking agent is injected around the bladder neck to cause narrowing and reduce leakage. It can be performed as an outpatient procedure and does not require a general anaesthetic or hospital stay. The most widely used bulking agent is polyacrylamide hydrogel (Bulkamid Õ ). This is a non-particulate gel. Other bulking agents may consist of silicone beads or other composite materials. Currently, NICE recommends that these are used for women in whom alternative surgical procedures are not suitable or not acceptable. However, many urogynaecologists will offer this procedure using Bulkamid Õ as a first line option, giving patients free choice. Success rates for polyacrylamide hydrogel bulking agents are slightly lower than the more invasive surgical options, and there is, as yet, limited data on long term effectiveness and adverse events compared with the other procedures available, but experts agree that the risks are less likely to be serious than with other operations (NICE, 2019a). . Failure of procedure to cure stress incontinence Adapted from Gray et al. (2019) .
InnovAiT NICE have highlighted the importance of shared decision making when approaching surgery for SUI. All women should be provided with clear written information about benefits and risks, long term adverse effects, expected hospital stay and recovery period for all available options. To aid this process NICE have provided a patient decision aid that allows patients to compare the pros and cons of the different options available. This is a 20-page booklet that comes with the 2019 NICE guidelines (NICE, 2019b) . There is also a user guide for patients available to supplement this information.
Primary care management of OAB syndrome and urge urinary incontinence
Lifestyle changes
There are a number of straightforward, well-evidenced lifestyle modifications that can result in a considerable improvement in symptoms. Avoiding bladder irritants, such as caffeine, carbonated drinks, tomato-based foods and some fruits, can help. Modifying fluid intake can help; reducing an excessive intake (which may be habitual), or increasing where low fluid intake (resulting in concentrated urine) may be irritating the bladder further. In women with a body mass index of over 30 kg/m 2 , weight loss can also improve incontinence symptoms.
Bladder re-training
Bladder re-training involves gradually increasing the length of time between voiding, so that the bladder is able to accommodate larger volumes of urine (patients with urgency symptoms often feel their bladder is full at lesser volumes than those without urgency symptoms). This can also help patients overcome learned behaviours such as emptying the bladder before leaving the house or getting in the car, which may contribute to becoming used to only being able to hold smaller volumes of urine. Bladder re-training courses are run in the primary care setting by community continence services and by specialist nurses within the secondary care setting. Primary care clinicians should utilise the community continence services available to their patients before considering referral to secondary care services.
Pharmacological treatments
Anticholinergic drugs are the first line treatment for OAB syndrome and should be initiated in primary care. Although the 2013 NICE guidance specified which anticholinergic drugs should be first treatment of OAB symptoms, the latest guidance has not offered specific drug choices. Instead it states that 'the anticholinergic with the lowest acquisition cost should be used', presumably taking into account the differences in commissioning between varying locations. It is noted that in women at increased risk of sudden deterioration of physical or mental health, immediate-release oxybutynin should not be offered. Before prescribing anticholinergic drugs, clinicians should reassess coexisting conditions, risk of adverse effects, and also any other medications being used which may affect total anticholinergic burden.
It is important that patients understand the potential side effects that may be experienced (e.g. dry mouth, blurred vision and constipation) and that they can be a sign of the Figure 1 . An image sequence demonstrating the working principles of the use of bladder neck bulking agents for SUI. The gel is injected into the neck of the bladder, forming small cushions that narrow the bladder neck and reduce stress leakage. medication working. Patients should be made aware that full benefits of treatment may not be seen for at least 4 weeks of treatment, and may improve further after this initial period. Furthermore, women should understand there are alternative medications to try, so they should return for review of symptoms and tolerability.
Recent studies have investigated the relationship between anticholinergic medications and cognitive impairment (Richardson et al., 2018) . A number of tools have been devised to enable clinicians to calculate the anticholinergic burden of medications, and NICE advises minimising the use of anticholinergic medications in patients being investigated for, or living with, dementia.
Mirabegron, a beta-3-adrenoceptor agonist, causes the bladder to relax, facilitating filling and storage of urine. NICE's 2013 technology appraisal guidance recommended its use for patients in whom anticholinergic drugs for OAB symptoms are contraindicated or clinically ineffective (NICE, 2013) . It can also be used for those in whom the side effects of anticholinergic drugs for OAB symptoms are unacceptable. It can also be used either in combination with an anticholinergic drug or as mono-therapy.
Women under 75 years of age on long term medication for OAB symptoms should have an annual medication review. Those over 75 years should be reviewed every 6 months. Patients with OAB symptoms or urgency incontinence who do not respond to bladder retraining and treatment with anticholinergics/beta-3 agonists should be referred to secondary care for review and second line management.
Invasive treatments for refractory OAB syndrome
Invasive treatments for urgency incontinence include the administration of intra-vesical botulinum toxin type A, sacral nerve stimulation (SNS), and percutaneous posterior tibial nerve stimulation (PTNS). Botulinum toxin is administered via injection during cystoscopy. This causes paralysis of the detrusor muscle at the areas where it is injected, reduced detrusor contractility and thus reducing or relieving OAB symptoms and urge incontinence. It is usually performed as an outpatient procedure under local anaesthetic. There is a 5-10% risk of urinary retention post treatment, so patients are taught how to self-catheterise before the procedure in case this occurs. This side-effect is usually temporary. The effect of the botulinum toxin wears off after 6-12 months, and is therefore repeated as required.
In women for whom botulinum toxin is unsuccessful or the risk of urinary retention and needing catheterisation not acceptable, neuromodulation may be considered after MDT review. Neuromodulation works by modifying or disrupting the nerve supply to the bladder, thus causing it to gradually reset. This reduces bladder contractility and reduces frequency and urgency, and increases bladder capacity. In PTNS, a needle electrode is placed above the ankle and attached to a stimulator. The treatment lasts around 30 minutes and is repeated weekly for 12 weeks. This is performed in an outpatient setting. SNS is far more effective, but more invasive; a small implanted device (around the size of a £2 coin) under the skin of the upper buttock, with wires placed near the sacral nerve roots (S2, S3 and S4), which provides low-voltage pulses. The insertion of the device is usually under general anaesthesia. A shortduration trial of a few weeks is undertaken using an external stimulation device, to confirm improvement of symptoms, before the long-term device is inserted.
Management of mixed urinary incontinence
Management of mixed urinary incontinence should be focussed on the predominant symptom, alongside lifestyle modifications and guided PFMT. Where stress incontinence is the predominant symptom, NICE guidance advises discussing the benefits of non-surgical management and pharmacological treatments for OAB syndrome, before offering surgery for SUI (NICE, 2019a) . Patients with mixed urinary incontinence should be referred to secondary care for a review and management under the care of the urogynaecologist if first line conservative management directed at the predominant symptom is not successful.
Toileting aids, absorbent containment products in women with incontinence NICE advises that toileting aids and absorbent containment products should be used only as an interim coping strategy whilemore definitive treatment is awaited, or as an adjunct to ongoing therapy (NICE, 2013 (NICE, , 2019b . They should be used long term for managing incontinence only after treatment options have been explored. Their use should be reviewed annually by a specialist healthcare professional (e.g. continence service) to assess their use, and whether suitable alternative treatments are available. The annual review should include assessment of skin integrity, as well as changes in medical co-morbidities, lifestyle, mobility and body mass index.
MDT working in urogynaecology
MDT meetings have long been proven of value in the management of cancer patients. Their use in benign conditions has become more widespread in recent years, as evidence of their benefits has emerged. The 2013 NICE guidance on urinary incontinence in women was the first publication to instruct on the need for MDT input prior to invasive procedures for urinary incontinence. The latest guidance has given further recommendations regarding organisation of services and multi-disciplinary work, defining regional team working for more complex cases, and local MDTs for primary management. The local MDT within a secondary care setting should involve two urogynaecologists, a specialist nurse and a pelvic floor specialist physiotherapist. Additional members whose contribution may be of benefit in planning patient care are noted to be a colorectal surgeon, a member of the care of the elderly team, and an occupational therapist, reflecting the impact of incontinence on holistic wellbeing, and influence of other co-morbidities on urinary symptoms. The regional MDT would specifically deal with complex pelvic floor dysfunction as well as mesh complications; hence, this team includes sub-specialist urogynaecologists, urologist with a special interest in female urology, a radiologist with expertise in pelvic floor imaging, a colorectal surgeon, and notably, a pain specialist with expertise in managing pelvic pain. This reflects the complex interplay of symptoms and their aetiology. Accordingly, NICE recommends that a Regional MDT has ready access to psychology and psychosexual counselling services, chronic pain management services and neurology. The changes in the latest NICE guidance reflect not only the response to emerging evidence regarding risks of treatment (anticholinergics, mesh complications), but also steer towards future organisation of services to reflect the higher specialist care that should be involved in managing patients with complex problems.
KEY POINTS
. It is important to determine the underlying type of incontinence to guide management
. First line treatments for urinary incontinence (such as anticholinergic drugs for urgency incontinence and supervised PFMT for stress incontinence) should be initiated in primary care
. Lifestyle modifications, such as weight loss, adjusting fluid intake, and bladder retraining are effective for OAB syndrome
. Supervised PFMT can be as effective as surgical treatments in up to 50% of women . Consider the anticholinergic burden of the patient's other medications when prescribing anticholinergic drugs for urgency incontinence/OAB
. There are well-evidenced effective surgical procedures available for SUI that do not use synthetic mesh
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